Tang Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Tang Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100,000	Closed	-$6.48M	–	106
2025 Q3	$6.48M	Buy	+100,000	New	+$5.74M	0.25%	86
2025 Q2	–	Sell	-266,500	Closed	-$9.07M	–	207
2025 Q1	$9.07M	Hold	266,500	–	–	0.5%	50
2024 Q4	$10.5M	Hold	266,500	–	–	0.69%	39
2024 Q3	$12.5M	Sell	266,500 -50,000	-16%	-$2.54M	0.89%	38
2024 Q2	$17.1M	Buy	316,500 +200,000	+172%	+$11.6M	1.74%	16
2024 Q1	$7.94M	Sell	116,500 -98,500	-46%	-$7.05M	0.83%	43
2023 Q4	$13.5M	Buy	+215,000	New	+$11.9M	1.24%	22
2023 Q3	–	Sell	-20,000	Closed	-$1.12M	–	111
2023 Q2	$1.12M	Buy	+20,000	New	+$1.13M	0.17%	80
2023 Q1	–	Sell	-10,000	Closed	-$407K	–	112
2022 Q4	$407K	Sell	10,000 -40,000	-80%	-$2.12M	0.06%	78
2022 Q3	$3.27M	Buy	+50,000	New	+$3.62M	0.4%	56

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

GSK plc London $599M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tang Capital Management's CRSP Position: Q4 2025 in Review

Tang Capital Management sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 100,000 shares — an estimated $6.48M sold.

Tang Capital Management first reported a position in CRSP in Q3 2022 and held it in 10 quarters. The position peaked at $17.1M in Q2 2024. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

Tang Capital Management reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
Tang Capital Management sold 100,000 CRISPR Therapeutics shares in Q4 2025, an estimated $6.48M.
Tang Capital Management first reported a position in CRISPR Therapeutics in Q3 2022 and held it in 10 quarters.
Tang Capital Management's CRISPR Therapeutics position peaked at $17.1M in Q2 2024.
479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.